Despite the fact that TSPAN8 has not been an available therapeutic target in HCC, there are several antibodies of TSPAN8 that may act as candidates for potential agents for colorectal cancer (CRC) and ovarian cancer. Here, TSPAN8 is linked to hepatocellular carcinoma.